• 1
    Goetzel RZ, Hawkins K, Ozminkowski RJ, Wang S. The health and productivity cost burden of the “top 10” physical and mental health conditions affecting six large U.S. employers in 1999. J Occup Environ Med 2003;45:514.
  • 2
    Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: Follow-up over 34–38 years. J Affect Disord 2002;68:167181.
  • 3
    Schou M. The combat of non-compliance during prophylactic lithium treatment. Acta Psychiatr Scand 1997;95:361363.
  • 4
    Guscott R, Taylor R. Lithium prophylaxis in recurrent affective illness. Efficacy, effectiveness and efficiency. Br J Psychiatry 1994;164:741746.
  • 5
    Scott J. Predicting medication non-adherence in severe affective disorders. Acta Neurolopsychiatr 2000;12:128130.
  • 6
    Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991;48:10821088.
  • 7
    Keck PE, McElroy S, Strakowski SM, et al. Factors associated with pharmacologic non-compliance in patients with mania. J Clin Psychiatry 1996;57:292297.
  • 8
    Jonhson R, McFarland B. Lithium use and discontinuation in a health maintenance organisation. Am J Psychiatry 1998;153:9931000.
  • 9
    Jamison KR, et al., Patient and physician attitudes toward lithium: Relationship to compliance. Arch Gen Psychiatry 1979;36:866869.
  • 10
    Thomson C, Peveler RC, Stephenson D, MC Kendrik J. Compliance with antidepressant medication in the treatment of major depressive disorder in primary care: A randomized comparison of fluoxetine and a tricyclic anti-depressant. Am J Psychiatry 2000;157:338343.
  • 11
    Lingam R & Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand 2002;105:164172.
  • 12
    Colom F, Vieta E, Martinez-Aran A, Reinares M, Benabarre A, Gast G. Clinical Factors Associated with treatment Noncompliance in Euthymic bipolar Patients. J Clin Psychiatry 2000;61:549555.
  • 13
    Keck PE, McElroy SL, Strakowski SM, Balistreri TM, Kizer DL. Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder. J Clin Psychiatry 1996;57:147151.
  • 14
    Strakowski SM, Keck PE, Mc Elroy SL. Twelve-month outcome after a first hospitalization for affective psychosis. Arch Gen Psychiatry 1988;55:4955.
  • 15
    Coppen A, Standish-Barry H, Bailey J, Houston G, Silcocks P, Hermon C. Does Lithium reduce the mortality of recurrent mood disorders? J Affect Disord 1991;23:17.
  • 16
    Isometsä E, Henriksson M, Lönnqvist J. Completed suicide and recent lithium treatment. J Affect Disord 1992;2:101103.
  • 17
    Jamison KR, Akiskal HS. Medication compliance in patients with bipolar disorder. Psychiatr Clin. North Am 1983;6:175192.
  • 18
    Jamison KR. Medication compliace. In: Goodwin FK, Jamison KR editors. Manic depressive illness. Oxford : Oxford University Press, 1990;746762.
  • 19
    Demyttenaere K. Compliance during treatment with antidepressants. J Affect Disord 1997;43:2739.
  • 20
    Knobel H, Alonso J, Casado JL, et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: The GEEMA Study. AIDS 2002;16:605613.
  • 21
    Ramos-Quiroga JA, Bosch R, Castells X, et al. Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate: A chart review of Spanish adults with attention-deficit hyperactivity disorder. CNS Drugs 2008;22:603611.
  • 22
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn., Washington : American Psychiatric Publishing, 1994.
  • 23
    Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382389.
  • 24
    Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry 1978;133:429435.
  • 25
    Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impression (CGI) Scale for use in bipolar illness (BP): The CGI-BP. Psychiatry Res 1997;73:159171.
  • 26
    Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24:6774.
  • 27
    Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity. Psychol Med 1983;13:177183.
  • 28
    Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: A re-examination comparing two measures. Psychol Med 1992;22:347352.
  • 29
    Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993;19:609618.
  • 30
    Sajatovic M, Rosch DS, Sivec HJ, et al. Insight into illness and attitudes toward medications among inpatients with schizophrenia. Psychiatr Serv 2002;53:13191321.
  • 31
    Hofer A, Kemmler G, Eder U, Honeder M, Hummer M, Fleischhacker WW. Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J. Clin. Psychiatry 2002;63:4953.
  • 32
    Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC. Attitudes of schizophrenia outpatients toward psychiatric medications: Relationship to clinical variables and insight. J Clin Psychiatry 2004;65:13721376.
  • 33
    Day JC, Bentall RP, Roberts C, et al. Attitudes toward antipsychotic medication: The impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry 2005;62:717724
  • 34
    Adewuya AO, Ola BA, Mosaku SK, Fatoye FO, Eegunranti AB. Attitude towards antipsychotics among out-patients with schizophrenia in Nigeria. Acta Psychiatr Scand 2006;113:207211.
  • 35
    Muller MJ. Attitudes toward different formulations of psychotropic drugs: The view of patients and healthcare providers. Am J Drug Deliv 2006;4:3341.
  • 36
    The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199208.
  • 37
    Brooks R, Rabin R, de Charro F. The measurement and valuation of health status using EQ-5D: A european perspective evidence from the EuroQol BIO MED research programme. Denmark: Kluwer Academic Publishers, 2003.
  • 38
    König HH, Roick C, Angermeyer MC. Validity of the EQ-5D in assessing and valuing health status in patients with schizophrenic, schizotypal or delusional disorders. Eur Psychiatry 2007;22:177187.
  • 39
    Günther O, Roick C, Angermeyer MC, König HH. The EQ-5D in alcohol dependent patients: Relationships among health-related quality of life, psychopathology and social functioning. Drug Alcohol Depend 2007;86:253264.
  • 40
    Supina AL, Johnson JA, Patten SB, Williams JV., Maxwell CJ. The usefulness of the EQ-5D in differentiating among persons with major depressive episode and anxiety. Qual Life Res 2007;16:749754.
  • 41
    Carta MG, Angst J. Epidemiological and clinical aspects of bipolar disorders: Controversies or a common need to redefine the aims and methodological aspects of surveys. Clin Pract Epidemiol Ment Health 2005;1:4.
  • 42
    Hosmer DW, Lemeshow S. Applied logistic regression, UK: Wiley Series in probability and statistics, Wiley & Sons, Inc., 2000.
  • 43
    Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during long-term lithium treatment: A meta-analytic review. Bipolar Disord 2006;8:625639.
  • 44
    Buckley PF, Correll CU. Strategies for dosing and switching antipsychotic for optimal clinical management. J Clin Psychiatry 2008;69(Suppl 1):417.
  • 45
    Hassan M, Lage MJ. Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge. Am J Health Syst Pharm 2009;66:358365.
  • 46
    Bellantuono C, Barraco A, Rossi A, Goetz I. The management of bipolar mania: A national survey of baseline data from the EMBLEM study in Italy. BMC Psychiatry 2007;7:3340.
  • 47
    Hayhurst H, Palmer S, Abbott R, Johnson T, Scott J. Measuring health-related quality of life in bipolar disorder: Relationship of the EuroQol (EQ-5D) to condition-specific measures. Qual Life Res 2006;15:12711280.
  • 48
    Kessing LV, Hansen HV, Bech P. General health and well-being in outpatients with depressive and bipolar disorders. Nord J Psychiatry 2006;60:150156.
  • 49
    Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. J Clin Psychiatry 2002;63:892909.
  • 50
    Sajatovic M, Valenstein M, Blow F, Ganoczy D, Ignacio R. Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder. Psychiatr Serv 2007;58:855863.
  • 51
    Mutsatsa SH, Joyce EM, Hutton SB, Webb E, Gibbins H, Paul S, Barnes TR. Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatr Scand 2003;108:439446.
  • 52
    Lage MJ, Hassan MK. The relationship between antipsychotic medication adherence and patient outcomes among individuals diagnosed with bipolar disorder: A retrospective study. Ann Gen Psychiatry 2009;18:78.
  • 53
    Pampallona S, Bollini P, Tibaldi G, Kupelnick B, Munizza C. Patient adherence in the treatment of depression. Br J Psychiatry 2002;180:104109.
  • 54
    Calabrese JR, Shelton MD, Rapport DJ, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005;162:21522162.
  • 55
    Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP. Strategies for addressing adherence problems in patients with serious and persistent mental illness: Recommendations from the expert consensus guidelines. J Psychiatr Pract 2010;16:306324.